Enfusion, Inc. (NYSE:ENFN) Stake Lessened by SG Americas Securities LLC

SG Americas Securities LLC trimmed its stake in shares of Enfusion, Inc. (NYSE:ENFN) by 72.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,929 shares of the company’s stock after selling 68,103 shares during the quarter. SG Americas Securities LLC’s holdings in Enfusion were worth $267,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. TenCore Partners LP acquired a new stake in shares of Enfusion during the 3rd quarter valued at approximately $3,938,000. Dimensional Fund Advisors LP increased its stake in Enfusion by 57.5% during the second quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company’s stock valued at $4,466,000 after purchasing an additional 191,436 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Enfusion by 612.4% during the third quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company’s stock valued at $1,974,000 after purchasing an additional 178,821 shares during the last quarter. Impax Asset Management Group plc raised its holdings in shares of Enfusion by 25.4% during the third quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock worth $6,424,000 after purchasing an additional 136,948 shares during the period. Finally, PDT Partners LLC bought a new position in shares of Enfusion in the 3rd quarter worth about $867,000. 81.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Oleg Movchan sold 2,771 shares of Enfusion stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total transaction of $28,070.23. Following the sale, the chief executive officer now directly owns 526,702 shares in the company, valued at $5,335,491.26. The trade was a 0.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Bradley Herring sold 24,443 shares of the company’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $10.61, for a total transaction of $259,340.23. Following the completion of the sale, the chief financial officer now directly owns 270,503 shares of the company’s stock, valued at $2,870,036.83. The trade was a 8.29 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 57,367 shares of company stock valued at $591,335. Insiders own 36.44% of the company’s stock.

Enfusion Stock Down 0.0 %

Shares of NYSE:ENFN opened at $11.19 on Thursday. Enfusion, Inc. has a fifty-two week low of $7.74 and a fifty-two week high of $11.38. The company has a market cap of $1.44 billion, a PE ratio of 279.69, a P/E/G ratio of 1.82 and a beta of 0.96. The company’s 50-day moving average price is $10.61 and its 200 day moving average price is $9.49.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on ENFN shares. Piper Sandler boosted their price objective on shares of Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research report on Monday, December 23rd. William Blair reaffirmed a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. Finally, Stifel Nicolaus raised their price target on Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat, Enfusion has a consensus rating of “Hold” and a consensus target price of $10.50.

Enfusion Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.